AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Glutathione S-transferase omega-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H4Y5

UPID:

GSTO2_HUMAN

Alternative names:

Glutathione S-transferase omega 2-2; Glutathione-dependent dehydroascorbate reductase; Monomethylarsonic acid reductase

Alternative UPACC:

Q9H4Y5; A8K771; B4DJW6; E7ESD6; Q49TW5; Q5GM70; Q5JU15; Q86WP3

Background:

Glutathione S-transferase omega-2 (GSTO2) is known for its critical enzymatic functions, including glutathione-dependent thiol transferase activity. It plays a pivotal role in cellular defense mechanisms by facilitating the recycling of ascorbic acid through its dehydroascorbate reductase activity. Additionally, GSTO2 is involved in the detoxification process, particularly in the biotransformation of inorganic arsenic, reducing monomethylarsonic acid (MMA).

Therapeutic significance:

Understanding the role of Glutathione S-transferase omega-2 could open doors to potential therapeutic strategies. Its involvement in crucial detoxification pathways and antioxidant processes highlights its potential as a target for developing treatments aimed at enhancing cellular defense mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.